BEECHAM'S BACTROBAN TOPICAL ANTIBIOTIC WILL BE LAUNED IN
BEECHAM'S BACTROBAN TOPICAL ANTIBIOTIC WILL BE LAUNED IN APRILfollowing FDA approval on Dec. 3, the company said. FDA review of the Bactroban NDA took 45 months. Bactroban (mupirocin) ointment 2%, Beecham said in a Jan. 7 press release, is "the first totally new antibiotic in a topical formulation to be introduced in the United States in more than 20 years." The approved labeling for Bactroban states that mupirocin ointment "is indicated for the topical treatment of impetigo due to: Staphylococcus aureus, beta hemolytic Streptococcus, and Streptococcus pyogenes." Impetigo is a highly contagious skin disease that affects over 1.3 million Americans a year, primarily children, Beecham said. The antibiotic has been tested in over 1,300 patients in U.S. clinical trials, Beecham said. An additional 10 clinicals are currently ongoing in the U.S. with Bactroban, the company added, to evaluate its effectiveness in treating other types of infections. Labeling for the antibiotic also notes that "each gram of Bactroban ointment 2% contains 20 mg mupirocin in a bland water miscible ointment base." Beecham's price to wholesalers for Bactroban is $22.50 per carton, which contains three, 15 gm tubes of the ointment.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth